Patents by Inventor Scott E. Lazerwith

Scott E. Lazerwith has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Thienopyrrole compounds
    Patent number: 11661431
    Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of an autoimmune disease and/or inflammatory condition, including systemic lupus erythematosus and cutaneous lupus erythematosus.
    Type: Grant
    Filed: April 15, 2022
    Date of Patent: May 30, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Stephen E. Ammann, Eda Y. Canales, Weng K. Chang, Henok H. Kinfe, Scott E. Lazerwith, Michael L. Mitchell, Yasamin Moazami, Scott D. Schroeder, Daniel G. Shore, Christopher J. Swank
  • SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF
    Publication number: 20230148157
    Abstract: This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.
    Type: Application
    Filed: July 12, 2022
    Publication date: May 11, 2023
    Inventors: David Alan Gutierrez, Tetsuya Kobayashi, Scott E. Lazerwith, Rick Andrew Lee, Philip Anthony Morganelli, Hyung-Jung Pyun
  • MCL-1 inhibitors
    Patent number: 11643400
    Abstract: The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.
    Type: Grant
    Filed: February 9, 2021
    Date of Patent: May 9, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Hang Chu, Juan A. Guerrero, Anna E. Hurtley, Tae H. Hwang, Lan Jiang, Darryl Kato, Tetsuya Kobayashi, John E. Knox, Scott E. Lazerwith, Xiaofen Li, David W. Lin, Jonathan W. Medley, Michael L. Mitchell, Devan Naduthambi, Zachary Newby, Neil H. Squires, Vickie H. Tsui, Chandrasekar Venkataramani, William J. Watkins, Hong Yang
  • POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE
    Publication number: 20230087744
    Abstract: Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, X, Y1, Y2, or L are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Application
    Filed: February 14, 2022
    Publication date: March 23, 2023
    Inventors: Mingzhe Ji, Scott E. Lazerwith, Hyung-Jung Pyun
  • CAPSID INHIBITORS FOR THE TREATMENT OF HIV
    Publication number: 20230038823
    Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of a Retroviridae viral infection, including an infection caused by the HIV virus.
    Type: Application
    Filed: June 24, 2021
    Publication date: February 9, 2023
    Applicant: Gilead Sciences, Inc.
    Inventors: Chienhung Chou, Darryl Kato, Scott E. Lazerwith, Scott D. Schroeder, Winston C. Tse, Jennifer R. Zhang
  • Substituted 1,4-methanopyrido[1?,2?:4,5]pyrazino[1,2-a]pyrimidines for treating viral infections
    Patent number: 11548901
    Abstract: Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, X, W, Y1, Y2, Z1, and Z4 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: May 6, 2020
    Date of Patent: January 10, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Elizabeth M. Bacon, Zhenhong R. Cai, Xiaowu Chen, Jeromy J. Cottell, Manoj C. Desai, Mingzhe Ji, Haolun Jin, Scott E. Lazerwith, Michael R. Mish, Philip Anthony Morganelli, Hyung-Jung Pyun, James G. Taylor, Teresa Alejandra Trejo Martin
  • THIENOPYRROLE COMPOUNDS
    Publication number: 20220389034
    Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of an autoimmune disease and/or inflammatory condition, including systemic lupus erythematosus and cutaneous lupus erythematosus.
    Type: Application
    Filed: April 15, 2022
    Publication date: December 8, 2022
    Inventors: Stephen E. Ammann, Eda Y. Canales, Weng K. Chang, Henok H. Kinfe, Scott E. Lazerwith, Michael L. Mitchell, Yasamin Moazami, Scott D. Schroeder, Daniel G. Shore, Christopher J. Swank
  • MCL-1 INHIBITORS
    Publication number: 20220340535
    Abstract: The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.
    Type: Application
    Filed: February 9, 2021
    Publication date: October 27, 2022
    Inventors: Hang Chu, Juan A. Guerrero, Anna E. Hurtley, Tae H. Hwang, Lan Jiang, Darryl Kato, Tetsuya Kobayashi, John E. Knox, Scott E. Lazerwith, Xiaofen Li, David W. Lin, Jonathan W. Medley, Michael L. Mitchell, Devan Naduthambi, Zachary Newby, Neil H. Squires, Vickie H. Tsui, Chandrasekar Venkataramani, William J. Watkins, Hong Yang
  • Substituted pyrrolizine compounds and uses thereof
    Patent number: 11420974
    Abstract: This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.
    Type: Grant
    Filed: October 14, 2020
    Date of Patent: August 23, 2022
    Assignee: Gilead Sciences, Inc.
    Inventors: David Alan Gutierrez, Tetsuya Kobayashi, Scott E. Lazerwith, Rick Andrew Lee, Philip Anthony Morganelli, Hyung-Jung Pyun
  • PHOSPHOLIPID COMPOUNDS AND USES THEREOF
    Publication number: 20220143052
    Abstract: Compounds and methods of using said compounds, alone or in combination with additional agents, and pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.
    Type: Application
    Filed: October 15, 2021
    Publication date: May 12, 2022
    Inventors: Scott E. Lazerwith, Jonathan William Medley, Philip A. Morganelli, Thomas P. Stratton, Peiyuan Wang
  • PHOSPHOLIPID COMPOUNDS AND USES THEREOF
    Publication number: 20220081455
    Abstract: Compounds and methods of using said compounds, singly or in combination with additional agents, and pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.
    Type: Application
    Filed: August 23, 2021
    Publication date: March 17, 2022
    Inventors: Scott E. Lazerwith, Jonathan William Medley, Philip A. Morganelli, Devan Naduthambi, Thomas P. Stratton, Peiyuan Wang
  • Crystalline forms of (2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1?,2?:4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
    Patent number: 11202780
    Abstract: The present invention relates to crystalline forms and co-crystals of (2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1?,2?:4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide, the pharmaceutical formulations, and the therapeutic uses thereof. The present invention also relates to novel crystalline forms of sodium (2R,5S,13aR)-7,9-dioxo-10-(2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1?,2?:4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate Form I.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: December 21, 2021
    Assignee: Gilead Sciences, Inc.
    Inventors: Ernest A. Carra, Irene Chen, Katie Ann Keaton, Scott E. Lazerwith, Vahid Zia
  • SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF
    Publication number: 20210251957
    Abstract: This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.
    Type: Application
    Filed: November 4, 2020
    Publication date: August 19, 2021
    Inventors: Jinfa DU, Joshua A. KAPLAN, Thorsten A. KIRSCHBERG, Tetsuya KOBAYASHI, Scott E. LAZERWITH, Rick Andrew LEE, Jonathan William MEDLEY, Michael L. MITCHELL, Philip Anthony MORGANELLI, Hyung-Jung PYUN, Sophia L. SHEVICK, Neil H. SQUIRES, William J. WATKINS
  • SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF
    Publication number: 20210147429
    Abstract: This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.
    Type: Application
    Filed: October 14, 2020
    Publication date: May 20, 2021
    Inventors: David Alan GUTIERREZ, Tetsuya KOBAYASHI, Scott E. LAZERWITH, Rick Andrew LEE, Philip Anthony MORGANELLI, Hyung-Jung PYUN
  • MCL-1 inhibitors
    Patent number: 10988451
    Abstract: The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.
    Type: Grant
    Filed: April 23, 2020
    Date of Patent: April 27, 2021
    Assignee: Gilead Sciences, Inc.
    Inventors: Hang Chu, Juan A. Guerrero, Anna E. Hurtley, Tae H. Hwang, Lan Jiang, Darryl Kato, Tetsuya Kobayashi, John E. Knox, Scott E. Lazerwith, Xiaofen Li, David W. Lin, Jonathan W. Medley, Michael L. Mitchell, Devan Naduthambi, Zachary Newby, Neil H. Squires, Vickie H. Tsui, Chandrasekar Venkataramani, William J. Watkins, Hong Yang
  • Synthesis of polycyclic-carbamoylpyridone compounds
    Patent number: 10975096
    Abstract: Methods of making compounds of Formula I are disclosed:
    Type: Grant
    Filed: November 18, 2019
    Date of Patent: April 13, 2021
    Assignee: Gilead Sciences, Inc.
    Inventors: Anna Chiu, John Enquist, Jr., Nolan Griggs, Christopher Hale, Norihiro Ikemoto, Katie Ann Keaton, Matt Kraft, Scott E. Lazerwith, Michel Leeman, Zhihui Peng, Kate Schrier, Jonathan Trinidad, Jochem Van Herpt, Andrew W. Waltman
  • POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE
    Publication number: 20210053988
    Abstract: Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, X, W, Y1, Y2, Z1, and Z4 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Application
    Filed: May 6, 2020
    Publication date: February 25, 2021
    Inventors: Elizabeth M. Bacon, Zhenhong R. Cai, Xiaowu Chen, Jeromy J. Cottell, Manoj C. Desai, Mingzhe Ji, Haolun Jin, Scott E. Lazerwith, Michael R. Mish, Philip Anthony Morganelli, Hyung-Jung Pyun, James G. Taylor, Teresa Alejandra Trejo Martin
  • POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE
    Publication number: 20210015816
    Abstract: Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (Ia): including stereoisomers and pharmaceutically acceptable salts thereof, wherein A?, R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Application
    Filed: March 27, 2020
    Publication date: January 21, 2021
    Inventors: Elizabeth M. Bacon, Zhenhong R. Cai, Jeromy J. Cottell, Mingzhe Ji, Haolun Jin, Scott E. Lazerwith, Philip Anthony Morganelli, Hyung-Jung Pyun
  • THERAPEUTIC COMPOUNDS
    Publication number: 20210009555
    Abstract: Compounds of formula (I) or salts thereof are disclosed. Also disclosed are pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus.
    Type: Application
    Filed: May 26, 2020
    Publication date: January 14, 2021
    Inventors: Gediminas Brizgys, Eda Canales, Chien-Hung Chou, Michael Graupe, Randall L. Halcomb, Yunfeng Eric Hu, Scott E. Lazerwith, John O. Link, Qi Liu, Yafan Lu, Roland D. Saito, Scott D. Schroeder, John R. Somoza, Winston C. Tse, Jennifer R. Zhang
  • Substituted pyrrolizine compounds and uses thereof
    Patent number: 10874640
    Abstract: This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.
    Type: Grant
    Filed: May 3, 2019
    Date of Patent: December 29, 2020
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Jinfa Du, Joshua A. Kaplan, Thorsten A. Kirschberg, Tetsuya Kobayashi, Scott E. Lazerwith, Rick Andrew Lee, Jonathan William Medley, Michael L. Mitchell, Philip Anthony Morganelli, Hyung-Jung Pyun, Sophia L. Shevick, Neil H. Squires, William J. Watkins